Approved Uses of BTKi Drugs in Hematologic Malignancies
BTK inhibitors have become an important class of targeted therapies for several blood cancers, including CLL, mantle cell lymphoma, and Waldenström's macroglobulinemia, with ongoing research expanding their potential role in hematology....
05 May, 2026